This week’s sweeping layoffs at the FDA have caused some biopharma leaders to change their tune on the Trump administration. After President Donald Trump’s victory in November, many biopharma CEOs ranged from cautious optimism to enthusiasm about more deals, rising markets and fewer regulations. But the first few months have been defined by industry leaders who either stayed silent or tried to find common ground. Tuesday’s federal cuts, which gutted divisions of the FDA and forced out many senior leaders with decades of institutional knowledge, prompted the beginnings of criticism from some of biopharma’s Trump backers.
Read the full article: FDA Cuts Stir Buyer’s Remorse for Some Biopharma Leaders, Once Excited by Trump //
Source: https://endpts.com/biopharma-execs-rethink-trump-impact-after-fda-cuts